NERV MINERVA NEUROSCIENCES

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Management to Host Conference Call

BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release fiscal year 2022 financial results and business updates on Wednesday, March 8, 2023. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.

The live conference call may be accessed and on the Company’s  under Events and Presentations.

The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences

Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our .

For more information:

Investor inquiries:                                                 

Fred Ahlholm                                                        

CFO, Minerva Neurosciences                                         

                 

Media Inquiries:

Helen Shik

Principal, Shik Communications LLC

 



EN
01/03/2023

Underlying

NERVMINERVA NEUROSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINERVA NEUROSCIENCES

 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Boar...

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company successfully raising up to $200 million in a private ...

November 19, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and...

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a , before deducting fees and other expenses. The financing includes an initial upfront funding of ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Announces Financing of up to $200 Million to Adv...

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved   Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 million proceeds may be received in connection with cas...

October 21, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Provides Business Updates and Second Quarter Fin...

Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with the FDA following (CRL) f...

August 14, 2025 1 EN
 PRESS RELEASE
Free
NERV MINERVA NEUROSC...

Minerva Neurosciences Reports First Quarter 2025 Financial Results and...

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025.    Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch